#USA #California #Class Action #Kessler Topaz #Hims & Hers

Class Action Lawsuit Against Hims & Hers Health, Inc.

Investors, take note: a significant class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) that could have serious implications for shareholders who acquired their securities within a defined timeframe. The allegations center around purported securities fraud that could affect those who purchased shares between August 4, 2025, and July 29, 2026. The deadline for affected investors to file for lead plaintiff status is looming on November 2, 2026.

Overview of the Case

The lawsuit, spearheaded by Kessler Topaz Meltzer & Check, LLP, has been officially registered at the United States District Court for the Northern District of California. Labeled as "Velanki v. Hims & Hers Health, Inc.," this legal action arises from alleged material misstatements and omissions that relate directly to the company's business practices.

Key Allegations

According to the court filings, the complaint outlines several serious charges:
1. Hims is accused of sharing sensitive consumer health information with third-party advertising platforms, raising significant privacy concerns.
2. The company allegedly charges consumers for prescriptions almost immediately after they submit an intake form, which contradicts their stated policy of allowing patients to consult with medical providers.
3. The conduct has reportedly drawn the scrutiny of regulatory bodies, suggesting a likelihood of incurring penalties and fees.
4. As a result of these actions, the positive claims made by Hims regarding its operations and future prospects have been deemed materially misleading.

Impact on Hims' Stock

On July 29, 2026, the Federal Trade Commission (FTC) filed a lawsuit against Hims, citing breaches of privacy laws and deceptive business practices. This unexpected announcement caused Hims's stock price to plummet by 14.73%, dropping $4.32 per share, and closing at $25.00. Investors are left to grapple with the ramifications of these legal challenges and their financial implications.

What Can Affected Investors Do?

If you are an investor in Hims & Hers Health, Inc. and feel impacted by these developments, it's crucial to consider your options:

• - File for Lead Plaintiff Status: Those who bought shares during the affected period can file to become the lead plaintiff by the closing deadline of November 2, 2026. This role involves representing all class members in directing the litigation.
• - Consult Legal Expertise: Kessler Topaz Meltzer & Check, LLP provides free case evaluations to help navigate the legal landscape. Their representation operates on a contingency fee basis, meaning there are no upfront costs to discuss your legal rights.
• - Retain Counsel of Your Choice: Investors may select to engage with Kessler Topaz or any legal counsel of their preference to explore recovery options or to simply remain passive participants in the class action.

Final Thoughts

This lawsuit reflects the broader issues surrounding investor rights and corporate responsibility within the healthcare industry. Hims & Hers Health, Inc. investors are encouraged to stay informed and actively pursue their options by the approaching deadline. For more information related to this case, or to engage legal counsel, contact Kessler Topaz Meltzer & Check, LLP. A client-friendly approach is taken to ensure that all expectations are handled professionally, providing investors the support they need during these uncertain times.

For inquiries, you can reach Jonathan Naji, Esq. at (484) 270-1453 or via email at [email protected]. Keep your interests protected and know your legal rights as the case develops.